NCT05259397View on ClinicalTrials.gov

PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 24, 2022

Primary Completion Date

September 19, 2022

Study Completion Date

September 19, 2022

Conditions
Bladder Cancer
Interventions
DRUG

PF-07225570

PF-07225570 given IVe in a 28-day cycle (as induction and maintenance regimen). Multiple dose levels will be evaluated.

DRUG

sasanlimab

Sasanlimab will be administered SQ on day 1 of each 28 day cycle.

Trial Locations (4)

10032

Columbia University Medical Center - Herbert Irving Pavilion, New York

CUMC Research Pharmacy, New York

02-544

Szpital Specjalistyczny im. Sw. Rodziny SPZOZ, Warsaw

02-798

Medical Concierge Centrum Medyczne, Warsaw

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05259397 - PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) | Biotech Hunter | Biotech Hunter